ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
- PMID: 32374633
- PMCID: PMC7462409
- DOI: 10.1164/rccm.201912-2460LE
ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
Comment in
-
Reply to Chang and Yew.Am J Respir Crit Care Med. 2020 Sep 1;202(5):778-779. doi: 10.1164/rccm.202003-0698LE. Am J Respir Crit Care Med. 2020. PMID: 32374628 Free PMC article. No abstract available.
Comment on
-
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST. Am J Respir Crit Care Med. 2019. PMID: 31729908 Free PMC article.
References
-
- Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, Baghaei P, et al. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392:821–834. - PMC - PubMed
-
- WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. - PubMed
-
- Nyang’wa BT, Berry C, Fielding K, Nunn AJ. Multidrug-resistant tuberculosis. Lancet. 2019;394:298–299. - PubMed
-
- Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, et al. TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J. 2009;34:387–393. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
